Vascular peroxidase 1/peroxidasin: A complex protein with a simple function?

Cardiovascular Research

Volumn 91, Issue 1, 2011, Pages 1-2

  Brandes, Ralf P ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXIDASE; PEROXIDASIN; UNCLASSIFIED DRUG; VASCULAR PEROXIDASE 1;

CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; EDITORIAL; ENZYME ACTIVITY; ENZYME ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANGIOTENSIN II; ANIMALS; CELL PROLIFERATION; EXTRACELLULAR MATRIX PROTEINS; HYPERTENSION; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PEROXIDASE;

EID: 79958775497     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr120     Document Type: Editorial

References (13)

1. Bindoli A, Fukuto JM, Forman HJ. Thiol chemistry in peroxidase catalysis and redox signaling. Antioxid Redox Signal 2008;10:1549-1564. (Pubitemid 351931936)
2. Davies MJ, Hawkins CL, Pattison DI, Rees MD. Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid Redox Signal 2008;10: 1199-1234. (Pubitemid 351634397)
3. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010;16: 470-474.
4. Cheng G, Salerno JC, Cao Z, Pagano PJ, Lambeth JD. Identification and characterization of VPO1, a new animal heme-containing peroxidase. Free Radic Biol Med 2008;45:1682-1694.
5. Shi R, Hu C, Yuan Q, Yang T, Peng J, Li Y et al. Involvement of vascular peroxidase 1 in angiotensin II-induced vascular smooth muscle cell proliferation. Cardiovasc Res 2011; 91:27-36.
6. Bekesi G, Heinle H, Kakucs R, Pazmany T, Szombath D, Dinya M et al. Effect of inhibitors of myeloperoxidase on the development of aortic atherosclerosis in an animal model. Exp Gerontol 2005;40:199-208. (Pubitemid 40343011)
7. Peterfi Z, Donko A, Orient A, Sum A, Prokai A, Molnar B et al. Peroxidasin is secreted and incorporated into the extracellular matrix of myofibroblasts and fibrotic kidney. Am J Pathol 2009;175:725-735.
8. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005;115:2223-2233. (Pubitemid 41134165)
9. Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E, Hayashi M, Saruta T. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res 2004;94:1067-1074. (Pubitemid 38579701)
10. Schaefer L. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol 2010;10:185-190.
11. Daiyasu H, Toh H. Molecular evolution of the myeloperoxidase family. J Mol Evol 2000;51:433-445.
12. Rodriguez C, Martinez-Gonzalez J, Raposo B, Alcudia JF, Guadall A, Badimon L. Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases. Cardiovasc Res 2008;79:7-13. (Pubitemid 351881945)
13. Brandes RP, Weissmann N, Schroder K. NADPH oxidases in cardiovascular disease. Free Radic Biol Med 2010;49:687-706.